Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Public ClinicalTrials.gov record NCT07220642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.
Study identification
- NCT ID
- NCT07220642
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2025 (Actual)
- Primary completion
- May 11, 2027 (Estimated)
- Completion
- Jun 29, 2027 (Estimated)
- Last update posted
- Aug 6, 2026
2025 – 2027
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | — |
| Univ of Colorado at Denver | Aurora | Colorado | 80045 | — |
| Florida Inst For Clin Res LLC | Orlando | Florida | 32825 | — |
| Oviedo Medical Research, LLC | Oviedo | Florida | 32765 | — |
| Walgreens - Store 11760 | Oak Park | Illinois | 60302 | — |
| Midwest Inst For Clin Res | Indianapolis | Indiana | 46260 | — |
| StudyMetrix Research LLC | City of Saint Peters | Missouri | 63303 | — |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | 27408 | — |
| Selma Medical Associates | Winchester | Virginia | 22601-3834 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07220642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2026 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07220642 live on ClinicalTrials.gov.